Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven patients in the trial Marks the latest in a series of regulatory successes in this indication, following FDA’s recognition of Alpha DaRT’s potential through its Breakthrough Device Designation for recurrent glioblastoma (GBM) and Alpha Tau’s selection for the FDA’s prestigious To

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update